Low-dose oral contraceptives and acquired resistance to activated protein C:: a randomised cross-over study

被引:214
作者
Rosing, J
Middeldorp, S
Curvers, J
Thomassen, MCLGD
Nicolaes, GAF
Meijers, JCM
Bouma, BN
Büller, HR
Prins, MH
Tans, G
机构
[1] Maastricht Univ, Cardiovasc Res Inst Maastricht, Dept Biochem, NL-6200 MD Maastricht, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands
[3] Univ Utrecht Hosp, Dept Haematol, Thrombosis & Haemostasis Lab, NL-3508 GA Utrecht, Netherlands
关键词
D O I
10.1016/S0140-6736(99)06092-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background We have reported previously that, compared with use of second-generation oral contraceptives, the use of third-generation oral contraceptives is associated with increased resistance to the anticoagulant action of activated protein C (APC). Owing to the cross-sectional design of that study, these observations may have been subject to unknown bias or uncontrolled effects of the menstrual cycle. We aimed to overcome these sources of bias by doing a cycle-controlled randomised cross-over trial. Methods The response to APC in plasma was assessed in 33 women who received two consecutive cycles of a second-generation oral contraceptive (150 mu g levonorgestrel and 30 mu g ethinyloestradiol) or a third-generation oral contraceptive (150 mu g desogestrel and 30 mu g ethinyloestradiol), and who switched preparations after two pill-free cycles. Normalised APC sensitivity ratios were calculated by measurement of the effect of APC on thrombin generation in the plasma of these women and in pooled plasma from 90 controls. Findings Of the 33 women,five were excluded because not all required plasma samples were available. in the remaining 28 women, the normalised APC sensitivity ratio increased during treatment with both preparations. Compared with levonorgestrel, desogestrel-containing oral-contraceptive treatment caused a highly significant (p<0.0001) additional increase in normalised APC sensitivity ratio (0.51 [95% CI 0.37-0.66]). Normalised APC sensitivity ratios during oral-contraceptive treatment correlated with the values before oral-contraceptive use. Interpretation Oral-contraceptive treatment diminishes the efficacy with which APC down-regulates in-vitro thrombin formation. This phenomenon, designated as acquired APC resistance, is more pronounced in women using desogestrel-containing oral contraceptives than in women using levonorgestrel-containing preparations. Whether acquired APC resistance induced by oral contraceptives explains the increased risk of venous thromboembolism in oral-contraceptive users remains to be established.
引用
收藏
页码:2036 / 2040
页数:5
相关论文
共 32 条
[1]  
[Anonymous], 2013, Clinical trials: a practical approach
[2]   MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].
BERTINA, RM ;
KOELEMAN, BPC ;
KOSTER, T ;
ROSENDAAL, FR ;
DIRVEN, RJ ;
DERONDE, H ;
VANDERVELDEN, PA ;
REITSMA, PH .
NATURE, 1994, 369 (6475) :64-67
[3]   ENHANCEMENT BY FACTOR-V LEIDEN MUTATION OF RISK OF DEEP-VEIN THROMBOSIS ASSOCIATED WITH ORAL-CONTRACEPTIVES CONTAINING 3RD-GENERATION PROGESTAGEN [J].
BLOEMENKAMP, KWM ;
ROSENDAAL, FR ;
HELMERHORST, FM ;
BULLER, HR ;
VANDENBROUCKE, JP .
LANCET, 1995, 346 (8990) :1593-1596
[4]   Acquired activated protein-C resistance in pregnancy and association with increased thrombin generation and fetal weight [J].
Clark, P ;
Walker, ID ;
Greer, I .
LANCET, 1999, 353 (9149) :292-293
[5]   FAMILIAL THROMBOPHILIA DUE TO A PREVIOUSLY UNRECOGNIZED MECHANISM CHARACTERIZED BY POOR ANTICOAGULANT RESPONSE TO ACTIVATED PROTEIN-C - PREDICTION OF A COFACTOR TO ACTIVATED PROTEIN-C [J].
DAHLBACK, B ;
CARLSSON, M ;
SVENSSON, PJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (03) :1004-1008
[6]   A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis [J].
de Visser, MCH ;
Rosendaal, FR ;
Bertina, RM .
BLOOD, 1999, 93 (04) :1271-1276
[7]  
FARLEY TMM, 1995, LANCET, V346, P1582
[8]   Population-based study of risk of venous thromboembolism associated with various oral contraceptives [J].
Farmer, RDT ;
Lawrenson, RA ;
Thompson, CR ;
Kennedy, JG ;
Hambleton, IR .
LANCET, 1997, 349 (9045) :83-88
[9]   Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism [J].
Heinemann, LAJ ;
Assmann, A ;
Spannagl, M ;
Schramm, W ;
Dick, A ;
Kluft, C ;
de Maat, MPM .
CONTRACEPTION, 1998, 58 (05) :321-322
[10]   RISK OF IDIOPATHIC CARDIOVASCULAR DEATH AND NONFATAL VENOUS THROMBOEMBOLISM IN WOMEN USING ORAL-CONTRACEPTIVES WITH DIFFERING PROGESTAGEN COMPONENTS [J].
JICK, H ;
JICK, SS ;
GUREWICH, V ;
MYERS, MW ;
VASILAKIS, C .
LANCET, 1995, 346 (8990) :1589-1593